Nexium 20mg + Nexium 10mg
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Erosive Esophagitis
Conditions
Erosive Esophagitis
Trial Timeline
Jul 1, 2022 → Sep 6, 2027
NCT ID
NCT05267613About Nexium 20mg + Nexium 10mg
Nexium 20mg + Nexium 10mg is a phase 3 stage product being developed by AstraZeneca for Erosive Esophagitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05267613. Target conditions include Erosive Esophagitis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05267613 | Phase 3 | Recruiting |
Competing Products
20 competing products in Erosive Esophagitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH1885L(Revaprazan) + Esomeprazole 20mg + placebo | Yuhan | Phase 2 | 52 |
| E3810 + E3810 + Placebo | Eisai | Phase 3 | 77 |
| RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM | Eisai | Phase 3 | 77 |
| Teprenone capsule and placebo of sucralfate + Sucralfate and placebo of teprenone | Eisai | Approved | 85 |
| ABT-981 + Placebo for ABT-981 | AbbVie | Phase 2 | 52 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Omeprazole | AstraZeneca | Phase 3 | 77 |
| AZD0865 | AstraZeneca | Phase 2 | 52 |
| Esomeprazole + Lansoprazole | AstraZeneca | Approved | 85 |
| Esomeprazole + Esomeprazole | AstraZeneca | Approved | 85 |
| AZD0865 | AstraZeneca | Phase 2 | 52 |
| esomeprazole magnesium (oral medication) | AstraZeneca | Approved | 85 |
| Alendronate Effervescent Oral Tablet | Amgen | Phase 2 | 51 |
| Omeprazole/sodium bicarbonate | Bausch Health | Approved | 80 |
| Vonoprazan | Phathom Pharmaceuticals | Phase 1 | 28 |
| Vonoprazan + Lansoprazole | Phathom Pharmaceuticals | Phase 3 | 72 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 2 | 47 |
| Vonoprazan | Phathom Pharmaceuticals | Pre-clinical | 18 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 3 | 72 |